相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy
Siri Tahtinen et al.
CANCER RESEARCH (2020)
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
Jing Ma et al.
CELL DEATH & DISEASE (2020)
Oncolytic Viruses and the Immune System: The Dynamic Duo
Ana Lemos de Matos et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
Victor Cervera-Carrascon et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Oncolytic viruses for cancer immunotherapy
Otto Hemminki et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients
Margarita Garcia et al.
HUMAN GENE THERAPY (2019)
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Guillem Pascual-Pasto et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
Jana de Sostoa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy
Yuefeng Yang et al.
HUMAN GENE THERAPY (2019)
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
Anna Morena D'Alise et al.
NATURE COMMUNICATIONS (2019)
Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
Alessandra Lopes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
Yonghui Zhang et al.
MOLECULAR THERAPY (2019)
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz Kuryk et al.
ONCOIMMUNOLOGY (2019)
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Meijun Zheng et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients
Sonia Tejada et al.
NEUROSURGERY (2018)
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results
Vignesh T. Packiam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. F. de Graaf et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!)
Alan Melcher
MOLECULAR THERAPY (2018)
For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough)
Stephen J. Russell
MOLECULAR THERAPY (2018)
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M. Ricca et al.
MOLECULAR THERAPY (2018)
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager
Anna Wing et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Giulia Marelli et al.
FRONTIERS IN IMMUNOLOGY (2018)
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
V. Cervera-Carrascon et al.
ONCOIMMUNOLOGY (2018)
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
Ahmed Abdullah Al-Zaher et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Janet Lei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors.
Manuel Ramirez et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)
Christopher Larson et al.
ONCOIMMUNOLOGY (2018)
Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges
N. A. Nixon et al.
CURRENT ONCOLOGY (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Oncolytic virus immunotherapy: future prospects for oncology
Junaid Raja et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model
Xiaozhu Li et al.
CLINICAL CANCER RESEARCH (2017)
Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization
Dominik Schoene et al.
JOURNAL OF VIROLOGY (2017)
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio Garcia-Carbonero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies
Joshua D. Freedman et al.
EMBO MOLECULAR MEDICINE (2017)
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
Hong Jiang et al.
CANCER RESEARCH (2017)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Carlos Alberto Fajardo et al.
CANCER RESEARCH (2017)
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
Cristian Capasso et al.
ONCOIMMUNOLOGY (2016)
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
Luis Alfonso Rojas et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses
Amber Miller et al.
MOLECULAR THERAPY (2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Juan J. Rojas et al.
CLINICAL CANCER RESEARCH (2015)
Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity
A. Rodriguez-Garcia et al.
GENE THERAPY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
Hanni Uusi-Kerttula et al.
VIRUSES-BASEL (2015)
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
L. Vassilev et al.
ONCOIMMUNOLOGY (2015)
Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
Alba Rodriguez-Garcia et al.
CLINICAL CANCER RESEARCH (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization
Tuuli Ranki et al.
ONCOIMMUNOLOGY (2014)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Jinpu Yu et al.
JOURNAL OF IMMUNOLOGY (2013)
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Ilkka Liikanen et al.
MOLECULAR THERAPY (2013)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
James M. Burke et al.
JOURNAL OF UROLOGY (2012)
An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2012)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity
Zachary C. Hartman et al.
CANCER RESEARCH (2010)
Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses
Juan J. Rojas et al.
MOLECULAR THERAPY (2010)
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus
Elena V. Shashkova et al.
CANCER RESEARCH (2008)
Factors influencing retention of adenovirus within tumours following direct intratumoural injection
M. Bazan-Peregrino et al.
GENE THERAPY (2008)
The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens
Reinhold Schirmbeck et al.
MOLECULAR THERAPY (2008)
Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation
Y. Endo et al.
ONCOGENE (2008)
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
Eric J. Small et al.
MOLECULAR THERAPY (2006)
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases
P Sova et al.
MOLECULAR THERAPY (2004)
Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region
LK Hawkins et al.
GENE THERAPY (2001)
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
J Nemunaitis et al.
GENE THERAPY (2001)
Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015):: results of Phase I and II trials
D Kirn
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
J Nemunaitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
NJ Tao et al.
MOLECULAR THERAPY (2001)
分享论文
